***Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Well, SRPT has delayed their decision past the PDUFA, destroying the weekly out-of-the-money (OTM) options traders counting on a decision. I debated making a play, but ultimately I was not comfortable. But that trade is over, where do we […]
Dave-Trading – May edition
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
Buy DeLo, Sell DeHigh – GILD Earnings
Last week I tweeted about an options play I made on $GILD earnings. I consulted with Dave, who said he was not expecting much of a move. The options were pricing a large move, so I made a lotto play. It was a 5-wide butterfly that cost me $250. As you can see from the […]
SRPT – Final thoughts ahead of the AdCom
Reaching the decision point… Today is the day we have to make decisions in SRPT position. As has been explained several times in the forum and CRG twitter private feed, the date of the panel is 04/25 and the FDA BD comes two days before the preliminary panel (2 business days), it should be […]
Dave-Trading – April Edition
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No positionPreview 2-3 […]
Cup O' Joe – GILD Calls
***Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Thesis: GILD has been in a channel between ~87 and ~91. Joe already has Apr. GILD $100 calls. To finish in the money, Joe needs an 11% move upward in 28 days. The time decay on these options […]
Dave-Trading BIIB
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Before we get to the meat of the trade, I want to address a recent question. How do I know how much capital to […]
Biotech Inflection Point – Watch List-2
Following my last technical analysis “Biotech Inflection Point – Watch List-1” I will keep adding names to our watch list with some beaten down tickers, we can find many deep value biotech stocks in the recent pullback, some are trading at or very close to their cash level, at this point their assets are […]
Buy DeLo, Sell DeHigh – RUT
*** Jason DeLorenzo is an income options trader. He trades on indexes mostly, but will trade positions based on CRG theses*** On 2/18 close to the market close, Joe tweeted this: “Joe @GantosJ Feb 18: The “Three Gaps Up” pattern $SPY $IBB $XBI is only a warning that exhaustion in the way, BUT expanding […]
Dave-Trading – PFE
Pfizer Inc. (PFE)–NYSE *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Options are unfairly seen as risky, and many value investors avoid options out of fear. David Sobek appears to be […]
Cup O' Joe – SRPT AdCom
***Our trading analyst Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Thesis: Joe has done a lot of research on SRPT. Despite some FDA headwinds, he believes the AdCom will at least be moderately positive for SRPT. But there is some downside risk, so there is […]
GILD – Heavy Options Activity
Gilead Sciences Inc. (GILD) –Nasdaq GILD dropping hard after MRK receive the FDA approval for a less expensive alternative to Gilead’s hepatitis C drug and pricing it with more than 30% discount to the competitor drugs from Gilead and ABBV. We notices a huge Feb 19th call options activity, with over 25K of $89 Call […]
Catalyst Watch – Vol. 3, Edition 9 (7/8/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: The company […]
Catalyst Watch – Vol. 3, Edition 8 (5/28/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: Several catalysts […]
Catalyst Watch – Vol. 3, Edition 7 (5/15/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: CNAT: Company has […]
Catalyst Watch – Vol. 3, Edition 6 (4/30/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: As expected, […]
Catalyst Watch – Vol. 3, Edition 5 (4/17/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: STRIDE trial […]
Catalyst Watch – Vol. 3, Edition 4 (4/3/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: Ampio has […]
Catalyst Watch – Vol. 3, Edition 3 (3/18/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: As mentioned, […]
Catalyst Watch – Vol. 3, Edition 2 (3/6/15)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: AMPE: Ampio has […]
